News - Boehringer Ingelheim, Shire

Filter

Current filters:

Boehringer IngelheimShire

Popular Filters

1 to 25 of 240 results

NDA filing for empagliflozin and linagliptin combo accepted by FDA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

14-04-2014

The US Food and Drug Administration has accepted the filing of the New Drug Application for the investigational…

Boehringer IngelheimDiabetesEli LillyempagliflozinJardiancelinagliptinNorth AmericaPharmaceuticalRegulationTradjentaUSA

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

07-04-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationUSA

Actavis prevails in Lialda patent dispute in USA

Actavis prevails in Lialda patent dispute in USA

31-03-2014

US generics major Actavis says that the US Court of Appeals for the Federal Circuit has reversed a lower…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsShireUSA

EMA/CHMP recommends empagliflozin for approval for type 2 diabetes

23-03-2014

German family-owned drug major Boehringer Ingelheim and partner Eli Lilly of the USA have announce a…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

06-03-2014

German family-owned pharma major Boehringer Ingelheim announced positive results from STARTVerso 4 in…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

05-03-2014

There was disappointment today for US drug major Eli Lilly and family-owned German pharma firm Boehringer…

Boehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaPharmaceuticalProductionRegulationUSA

New Ph III data show tiotropium Respimat effective across asthma severities

03-03-2014

German family-owned drug major Boehringer Ingelheim has released new data from large scale, Phase III…

Boehringer IngelheimPharmaceuticalResearchRespimatRespiratory and Pulmonarytiotropium

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

20-02-2014

US clinical-stage biotech firm Vitae Pharmaceuticals says it has earned a $14 million milestone payment…

BiotechnologyBoehringer IngelheimFinancialNeurologicalResearchVitae Pharmaceuticals

UK’s MHRA accepts Shire’s Elvanse filing for ADHD in adults

UK’s MHRA accepts Shire’s Elvanse filing for ADHD in adults

19-02-2014

Ireland-headquartered drugmaker Shire has had an application for its once-daily attention deficit/hyperactivity…

ElvanseNeurologicalPharmaceuticalRegulationShire

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

19-02-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG), in an early benefit assessment…

Boehringer IngelheimGermanyGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulation

Shire CFO Graham Hetherington to step down

Shire CFO Graham Hetherington to step down

13-02-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Graham Hetherington, chief financial…

BoardroomNorthern EuropePharmaceuticalShire

Shire posts top year-end results and expects earnings to rise again in 2014

Shire posts top year-end results and expects earnings to rise again in 2014

13-02-2014

Ireland-headquartered drugmaker Shire has recorded a rise in sales and earnings to deliver strong full-year…

DermagraftFinancialFirazyrIntunivLialdaMezavantNorthern EuropePharmaceuticalShireViroPharmaVprivVyvanse

Shire will drop MDD indication for Vyvanse after failed endpoints in Ph III

07-02-2014

Shares of Ireland-headquartered Shire fell 2.4% to £30.67 in early trading, after the company presented…

NeurologicalPharmaceuticalResearchShireVyvanse

Susan Kilsby to succeed Matthew Emmens as chairman of Shire

Susan Kilsby to succeed Matthew Emmens as chairman of Shire

23-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Susan Kilsby will become non-executive…

BoardroomEuropePharmaceuticalShire

“Differing views” see Zealand and Boehringer change collaboration compound

“Differing views” see Zealand and Boehringer change collaboration compound

20-01-2014

Zealand Pharma and Boehringer Ingelheim will change the development program involving novel glucagon/GLP-1…

Boehringer IngelheimDenmarkDiabetesGermanyPharmaceuticalResearchZealand Pharma

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments

17-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

FORMA meets milestones under Boehringer Ingelheim cancer accord

FORMA meets milestones under Boehringer Ingelheim cancer accord

10-01-2014

US drug discovery company FORMA Therapeutics revealed that it has achieved several discovery milestones…

Boehringer IngelheimFORMA TherapeuticsLicensingOncologyPharmaceuticalResearch

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

17-12-2013

New data show that family-owned German drug major Boehringer Ingelheim’s second-generation protease…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalResearch

Report: Life science companies experience IPO slowdown

10-12-2013

Life sciences companies have been completing fewer initial public offerings (IPOs) this season as the…

Mergers & AcquisitionsPharmaceuticalRocheSalix PharmaceuticalsShireUSA

Shire reports mixed results from Phase III study of lifitegrast in dry eye disease

Shire reports mixed results from Phase III study of lifitegrast in dry eye disease

09-12-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced mixed results from a Phase III efficacy…

EuropeLifitegrastOphthalmicsPharmaceuticalResearchShire

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

03-12-2013

UK drugmaker Shire says that its subsidiary Shire US Inc has entered into an agreement to supply an authorized…

Adderall XRGenericsLicensingNeurologicalNorth AmericaNovartisSandozShire

1 to 25 of 240 results

Back to top